MedTrace Logo

Atorvastatin as an Antihypertensive Agent

NCT05679102 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-01-10

No results posted yet for this study

Summary

This study is aimed to see the antihypertensive effect of statin (Atorvastatin) as certain animal models have shown that statins have the voltage-gated calcium channel blocking effect. It will be a randomized controlled trial that will be done in Ayub Hospital Complex Abbottabad. After ethical approval, 120 patients with newly diagnosed hypertension belonging to either gender and aged 35 and above will be enrolled in the trial. They will randomly be grouped into two groups with each group comprising 60 patients. One group will be administered Amlodipine 5 mg PO once a day, while the other one will be given 5mg Amlodipine plus 10 mg Atorvastatin. The patients will be examined on a follow-up visit 14 days later and blood pressure will be recorded as per protocols.

Conditions

  • Atorvastatin Antihypertensive Effect

Interventions

DRUG

Amlodipine 5 MG Oral Tablet

one group will be given only Amlodipine 5MG once daily

DRUG

Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet

one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily

Sponsors & Collaborators

  • Ayub Teaching Hospital

    collaborator OTHER

  • Khyber Medical University Peshawar

    collaborator OTHER

  • Himayat Ullah

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-20
Primary Completion
2023-01-04
Completion
2023-01-04

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05679102 on ClinicalTrials.gov